Abstract
In the above article, we noticed that one female patient in the positive group (plasma lyso-Gb3 7.6 ng/ml, α-galactosidase A activity 4.9 nmol/h/ml) who presented at the neurology clinic was already diagnosed with Fabry disease before the current study. We excluded patients with a confirmed diagnosis of Fabry disease and those with relatives known to have Fabry disease. To accurately describe the information in the current study, we must exclude this patient from the analysis. We have accurately revised this information as follows:
| Original language | English |
|---|---|
| Pages (from-to) | 512-515 |
| Number of pages | 4 |
| Journal | Genetics in Medicine |
| Volume | 21 |
| Issue number | 2 |
| DOIs |
|
| Publication status | Published - Feb 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Genetics(clinical)
Cite this
Correction : Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31). / Maruyama, Hiroki; Miyata, Kaori; Mikame, Mariko; Taguchi, Atsumi; Guili, Chu; Shimura, Masaru; Murayama, Kei; Inoue, Takeshi; Yamamoto, Saori; Sugimura, Koichiro; Tamita, Koichi; Kawasaki, Toshihiro; Kajihara, Jun; Onishi, Akifumi; Sugiyama, Hitoshi; Sakai, Teiko; Murata, Ichijiro; Oda, Takamasa; Toyoda, Shigeru; Hanawa, Kenichiro; Fujimura, Takeo; Ura, Shigehisa; Matsumura, Mimiko; Takano, Hideki; Yamashita, Satoshi; Matsukura, Gaku; Tazawa, Ryushi; Shiga, Tsuyoshi; Ebato, Mio; Satoh, Hiroshi; Ishii, Satoshi.
In: Genetics in Medicine, Vol. 21, No. 2, 01.02.2019, p. 512-515.Research output: Contribution to journal › Comment/debate
}
TY - JOUR
T1 - Correction
T2 - Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31)
AU - Maruyama, Hiroki
AU - Miyata, Kaori
AU - Mikame, Mariko
AU - Taguchi, Atsumi
AU - Guili, Chu
AU - Shimura, Masaru
AU - Murayama, Kei
AU - Inoue, Takeshi
AU - Yamamoto, Saori
AU - Sugimura, Koichiro
AU - Tamita, Koichi
AU - Kawasaki, Toshihiro
AU - Kajihara, Jun
AU - Onishi, Akifumi
AU - Sugiyama, Hitoshi
AU - Sakai, Teiko
AU - Murata, Ichijiro
AU - Oda, Takamasa
AU - Toyoda, Shigeru
AU - Hanawa, Kenichiro
AU - Fujimura, Takeo
AU - Ura, Shigehisa
AU - Matsumura, Mimiko
AU - Takano, Hideki
AU - Yamashita, Satoshi
AU - Matsukura, Gaku
AU - Tazawa, Ryushi
AU - Shiga, Tsuyoshi
AU - Ebato, Mio
AU - Satoh, Hiroshi
AU - Ishii, Satoshi
PY - 2019/2/1
Y1 - 2019/2/1
N2 - In the above article, we noticed that one female patient in the positive group (plasma lyso-Gb3 7.6 ng/ml, α-galactosidase A activity 4.9 nmol/h/ml) who presented at the neurology clinic was already diagnosed with Fabry disease before the current study. We excluded patients with a confirmed diagnosis of Fabry disease and those with relatives known to have Fabry disease. To accurately describe the information in the current study, we must exclude this patient from the analysis. We have accurately revised this information as follows:
AB - In the above article, we noticed that one female patient in the positive group (plasma lyso-Gb3 7.6 ng/ml, α-galactosidase A activity 4.9 nmol/h/ml) who presented at the neurology clinic was already diagnosed with Fabry disease before the current study. We excluded patients with a confirmed diagnosis of Fabry disease and those with relatives known to have Fabry disease. To accurately describe the information in the current study, we must exclude this patient from the analysis. We have accurately revised this information as follows:
UR - http://www.scopus.com/inward/record.url?scp=85061209550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061209550&partnerID=8YFLogxK
U2 - 10.1038/s41436-018-0125-2
DO - 10.1038/s41436-018-0125-2
M3 - Comment/debate
VL - 21
SP - 512
EP - 515
JO - Genetics in Medicine
JF - Genetics in Medicine
SN - 1098-3600
IS - 2
ER -